切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2021, Vol. 17 ›› Issue (01) : 1 -6. doi: 10.3877/cma.j.issn.1673-5250.2021.01.001

所属专题： 文献；

述评

聚腺苷酸二磷酸核糖聚合酶抑制剂在复发性卵巢癌维持治疗中的作用
宫晗1,1, 聂丹2,2, 黄玥1,1, 李征宇1,†,1()   
  • 收稿日期:2020-03-22 修回日期:2020-11-09 出版日期:2021-02-01
  • 通信作者: 李征宇

Roles of poly ADP-ribose polymerase inhibitors in maintenance treatment for recurrent ovarian cancer

Han Gong1,1, Dan Nie2,2, Yue Huang1,1, Zhengyu Li1,1,†()   

  • Received:2020-03-22 Revised:2020-11-09 Published:2021-02-01
  • Corresponding author: Zhengyu Li
  • Supported by:
    Scientific Research Project of Science and Technology Department of Sichuan Province(19YYJC2397); Clinical Research Project of West China Second University Hospital, Sichuan University(KL040)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

宫晗, 聂丹, 黄玥, 李征宇. 聚腺苷酸二磷酸核糖聚合酶抑制剂在复发性卵巢癌维持治疗中的作用[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(01): 1-6.

Han Gong, Dan Nie, Yue Huang, Zhengyu Li. Roles of poly ADP-ribose polymerase inhibitors in maintenance treatment for recurrent ovarian cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2021, 17(01): 1-6.

奥拉帕利(olaparib)、卢卡帕利(rucaparib)及尼拉帕利(niraparib)均为聚腺苷酸二磷酸核糖聚合酶抑制剂(PARPi)，是一类具有广阔发展前景的新型抗癌药物。PARPi通过靶向抑制细胞核内的聚腺苷酸二磷酸核糖聚合酶(PARP)，从而特异性杀死同源重组修复通路(homologous recombination repair pathway)缺陷的癌细胞。在我国，卢卡帕利已完成临床试验，奥拉帕利及尼拉帕利则于2019年被中国国家药品监督管理局(NMPA)正式批准，用于对铂类药物敏感的复发性卵巢癌患者的维持治疗。中国目前仍缺乏对此类药物的临床应用经验。这3种药物均已在美国、欧洲、中国香港地区上市，并已完成临床试验研究阶段。笔者拟就目前PARPi在卵巢癌治疗过程中的适用人群、疗效及安全性等研究现状进行详细阐述，旨在为PARPi在临床进一步推广、应用提供参考。

关键词: 聚ADP核糖聚合酶类, 聚ADP核糖聚合酶抑制剂, 卵巢肿瘤, 突变, 奥拉帕利, 卢卡帕利, 尼拉帕利, 维持治疗

Poly ADP-ribose polymerase inhibitor (PARPi), such as olaparib, rucaparib and niraparib are brand-new anticancer drugs with great potential. Through targeting intranuclear poly ADP-ribose polymerase (PARP), PARPi, which have made remarkable achievements in treatment of cancers, have the unique ability to selectively kill cancer cells with deficiency of homologous recombination repair pathway. However, clinical trial of rucaparib has been completed in China, and olaparib and niraparib have been approved by the National Medical Products Administration (NMPA) of China in 2019 for maintenance treatment of patients with relapsed ovarian cancers. We are still lack of clinical experience in application of PARPi. This article aims to give a comprehensive description of the suitable population, efficacy and safety of PARPi in treatment of ovarian cancers, in order to provide reference for their following widespread use.

Key words: Poly (ADP-ribose) polymerases, Poly (ADP-ribose) polymerase inhibitors, Ovarian neoplasms, Olaparib, Rucaparib, Niraparib, Maintenance therapy
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]
Wiggans AJ, Cass GK, Bryant A, et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer [J]. Cochrane Database Syst Rev, 2015, (5): CD007929. DOI: 10.1002/14651858.CD007929.pub3.
[3]
Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2018, 29(Suppl 4): iv259. DOI: 10.1093/annonc/mdy157.
[4]
Bürkle A. Poly (ADP-ribose). The most elaborate metabolite of NAD+[J]. FEBS J, 2005, 272(18): 4576-4589. DOI: 10.1111/j.1742-4658.2005.04864.x.
[5]
Jain PG, Patel BD. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update [J]. Eur J Med Chem, 2019, 165: 198-215. DOI: 10.1016/j.ejmech.2019.01.024.
[6]
Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what′s next after PARP inhibitors? [J]. Nat Rev Clin Oncol, 2018, 15(9): 564-576. DOI: 10.1038/s41571-018-0055-6.
[7]
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial [J]. Lancet Oncol, 2014, 15(8): 852-861. DOI: 10.1016/S1470-2045(14)70228-1.
[8]
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer [J]. N Engl J Med, 2016, 375(22): 2154-2164. DOI: 10.1056/NEJMoa1611310.
[9]
Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2017, 18(1): 75-87. DOI: 10.1016/S1470-2045(16)30559-9.
[10]
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [J]. N Engl J Med, 2018, 379(26): 2495-2505. DOI: 10.1056/NEJMoa1810858.
[11]
Guo XX, Wu HL, Shi HY, et al. The efficacy and safety of olaparib in the treatment of cancers: a Meta-analysis of randomized controlled trials [J]. Cancer Manag Res, 2018, 10: 2553-2562. DOI: 10.2147/CMAR.S169558.
[12]
Qin W, Wu HJ, Cao LQ, et al. Research progress on PARP14 as a drug target [J]. Front Pharmacol, 2019, 10: 172. DOI: 10.3389/fphar.2019.00172.
[13]
Motegi A, Masutani M, Yoshioka KI, et al. Aberrations in DNA repair pathways in cancer and therapeutic significances [J]. Semin Cancer Biol, 2019, 58: 29-46. DOI: 10.1016/j.semcancer.2019.02.005.
[14]
Lee JY, Yi JY, Kim HS, et al. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION [J]. Jpn J Clin Oncol, 2019, 49(8): 789-792. DOI: 10.1093/jjco/hyz085.
[15]
Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer [J]. N Engl J Med, 2019, 381(25): 2416-2428. DOI: 10.1056/NEJMoa1911361.
[16]
Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer [J]. N Engl J Med, 2019, 381(25): 2403-2415. DOI: 10.1056/NEJMoa1909707.
[17]
González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer [J]. N Engl J Med, 2019, 381(25): 2391-2402. DOI: 10.1056/NEJMoa1910962.
[18]
Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial [J]. Lancet Oncol, 2019, 20(10): 1409-1419. DOI: 10.1016/S1470-2045(19)30515-7.
[19]
Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2017, 18(9): 1274-1284. DOI: 10.1016/S1470-2045(17)30469-2.
[20]
LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors [J]. Lancet Oncol, 2019, 20(1): e15-e28. DOI: 10.1016/S1470-2045(18)30786-1.
[1] 庞嘉越成, 巨淑慧, 马冀青, 李恒宇, 盛湲. 乳腺癌易感基因突变人群接受降低乳腺癌风险手术的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(03): 179-183.
[2] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[3] 陈甜甜, 王晓东, 余海燕. 双胎妊娠合并Gitelman综合征孕妇的妊娠结局及文献复习[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 559-568.
[4] 陈荟竹, 郭应坤, 汪昕蓉, 宁刚, 陈锡建. 上皮性卵巢癌"二元论模型"的分子生物学研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 394-402.
[5] 刘星辰, 刘娟, 魏宝宝, 刘洁, 刘辉. XIAP与XAF1异常表达与卵巢癌的相关性分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 419-427.
[6] 阚路兰, 田茂强, 唐一蜜. 以腹痛为首发症状的轻型Gitelman综合征患儿1例及文献复习[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 473-479.
[7] 张小曼, 马筱秋, 许正锯, 张纯瑜, 何彩婷. 乙型肝炎病毒逆转录酶区耐药突变对血清乙型肝炎病毒表面抗原水平的影响[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 324-332.
[8] 袁育韬, 邢金琳, 谢克飞, 殷凯. CT征象及BRAFV600E基因突变与甲状腺乳头状癌中央区淋巴结转移的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 611-614.
[9] 杨晓健, 张炎, 冯嘉荣, 刘卓杰, 张浩. 先天性输精管缺如合并肾脏畸形三例CFTR基因突变检测并文献复习[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(02): 110-113.
[10] 汪涛, 朱浩雨, 卜青松, 胡磊, 王文娟, 方阮, 刘啸峰. 非小细胞肺癌EGFR突变状态与CT特征的相关性[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 51-54.
[11] 陈润芝, 杨东梅, 徐慧婷. 信迪利单抗联合索凡替尼后线治疗MSS型BRAF突变的转移性结肠癌：个案报道并文献复习[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 431-435.
[12] 刘育昕, 王子晗, 张艺馨, 栾永婕, 孟凯. 肾母细胞瘤基因1在卵巢疾病发病机制中的研究进展[J]. 中华诊断学电子杂志, 2023, 11(03): 178-183.
[13] 王倩, 王永萍, 李新培, 杨成艳, 许慧, 孙凤娟, 刘亚平. 伴基因突变的低钾血症诊断学特征分析[J]. 中华诊断学电子杂志, 2023, 11(02): 115-119.
[14] 王可珺, 李吉镇, 马标, 续慧超, 谌红珊, 刘雷. 肌酐/胱抑素C对晚期上皮性卵巢癌术后并发症的预测价值[J]. 中华诊断学电子杂志, 2023, 11(01): 49-55.
[15] 滕振, 闫波. 转录因子HAND1基因多态性在心血管疾病中的研究进展[J]. 中华诊断学电子杂志, 2023, 11(01): 5-11.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号